RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Investor Presentation (November 2022)

38 slides from RespireRx Pharmaceuticals's investor presentation, Nov 7, 2022

  1. Slide 1: RespireRx Pharmaceuticals Inc, November 8, 2022

    ad sd i a Y Pharmaceuticals Inc November 8, 2022

  2. Slide 2: Cautionary Notes: Forward Looking Statements

    CAUTIONARY NOTES GAS) RespireRx Pharmaceuticals Inc FORWARD LOOKING STATEMENTS This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchonge Act of 1934, 0s a

  3. Slide 3: Cautionary Notes (cont'd): Not a Securities Offering

    TTIONARY NOTES (cont’d) oS) RespireRx Pharmaceuticals Inc NOT A SECURITIES OFFERING This presentation is being provided for informational purposes only. This presentation does not constitute an offer to sel a solicitation of an offer to buy, or a recommendation of any security or any other product o

  4. Slide 4: Project Endeavor - Neuromodulators Can Enhance Synaptic Transmission

    Project Endeavor - Neuromodulators Resp pireRx Pharmaceuticals Inc Neuromodulators Can Enhance Synaptic Transmission * Neurons communicate by releasing chemical neurotransmitters that bind to specific receptors on the adjacent neuron. * Glutamate is the major excitatory neurotransmitter and GABA is

  5. Slide 5: Project Endeavor - Ampakines: Identify Target

    Project Endeavor - Ampakines RespireRx 4 Pharmaceuticals Inc 1. Identify Target RespireRx Pharmaceuticals Inc © Medicines for Respiratory Diseases

  6. Slide 6: Ampakines - A Novel Class of Drugs

    RespireRx respires Inc AMPAKINES - A NOVEL CLASS OF DRU BR AMPAKINE o Glutamate is the major excitatory neurotransmitter in the CNS — o Fast excitatory transmission is mediated by AMPA-type glutamate ~~ receptors Postsynaptic o Ampakines are positive, allosteric modulators of the AMPA-type glutamate

  7. Slide 7: AMPA Glutamate Receptor Structure

    AMPA Glutamate Receptor Structure The AMPA receptor is composed of four transmembrane proteins that form a pore, which when activated by glutamate opens and allows positive ions to enter the cell. Ampakine binding sites are located adjacent to the glutamate binding sites and increase the normal exci

  8. Slide 8: AMPA Receptor - Physiology

    AMPA Receptor - Physiology RespireRx Pharmaceuticals Inc Deactivation ‘Lms Pulse ' ' — Baseline Desensitization 500 ms Pulse Baseline Effects of CX614 and CTZ were examined in patches excised from hippocampal CA1 pyramidal neurons.

  9. Slide 9: Project Endeavor - Ampakines: Design Drugs

    Project Endeavor - Ampakines RespireRx 4 Pharmaceuticals Inc 1. Identify Target 2. Design Drugs RespireRx Pharmaceuticals Inc © Medicines for Respiratory Diseases

  10. Slide 10: The Lego School of Drug Design

    The Lego School of Drug Design ®)RespireRx Pharmaceuticals Inc cyclothiazide cx546 cxe14 Neurosearch Lilly: LY392098 OP 04.0 sf ° a Tal 0. A 0. Rv. Xa R2 oO OR, COO 6D X OOK od cL, Qh, re As vd RS H High Impact Aniracetam-Roche CX516- Ampalex™ x717 x1739 €X1942/CX1763 . 4 ° ° Ns Ld sory Os ARH b sot

  11. Slide 11: Ampakines - High Impact

    AMPAKINES - High Impact DN RespireRx Pharmaceuticals Inc A CX614 cyclothiazide ee emule = . F oe Q B deactivation time constant (ms) f 2 53 "f wml Om |) 4 wi 20msec ee oe 20. msec Effects of CX614 and CTZ were examined in patches excised from hippocampal CA1 pyramidal neurons. Patches were equilibra

  12. Slide 12: Ampakines - Low Impact

    RespireRx Pharmaceuticals Inc AMPAKINES - Low Impact GAN 1mM glutamate cxe14 A Ce + 30 pM CX 717, ies 100 pa 200 ms wm B 0 D % steady-state current : 200 = [emote gf es £ i 7 3 2 150 2 3 100 #10 2 50 z a ° a 1 10 400 oat 100 CX 717 (uM) [CX614] (uM) "j000

  13. Slide 13: Ampakines - Low Impact: CX1739

    AMPAKINES - Low Impact (Resp pireRx Pharmaceuticals Inc acwamps: cx1739 50 pA ‘Amp (pA) — Time (min) Effects of Cx1739 on AMPAR-mediated currents in CA1 pyramidal neurons. A, In the presence of TTX (1 41M), puffing AMPA (0.5 mM, 4 ms pulse, 0.1-0.2 psi) induced a fast current (Black trace and 1) tha

  14. Slide 14: High Impact Ampakines - Tissue Model of Convulsions

    High Impact Ampakines —- Tissue Model of Convulsions GQ) Resp pireRx Pharmaceuticals Inc PTX wash x14 wash. ” Voand rat heen ™ ‘ aro if | a8 is ; commen sumo Amplitude (pA) o o 20 a 6 Boa 1 3 Tinh 2. ——— pe ° o 20 0 © 20 100 Time (min) Extracellular field potentials (Population Spikes) from CA1 pyra

  15. Slide 15: Low Impact Ampakines - Tissue Model of Convulsions

    Low Impact Ampakines - Tissue Model of Convulsions WR RespireRx pespiren Inc Seizure Potential of CX717-701 (SSPA) Control 717-300 701-300 717-600 701-600 pe as eae) 717-300 , 717-600, 3.0, H 1-300 PL (mv) P2 (mv) 0 400 200 300 400 500 Trials (20s)

  16. Slide 16: Seizure Potential of CX1739

    ow Impact Ampakines - Tissue Model of Convulsi NR RespireRx pespiren Inc Seizure Potential of CX1739 4r 100 200 if oH g sf | | i a 3 Soni aanmed| (mv) 2 ee 1S cee a ° 1p H "2 (mv) 2 oO 50 100 150 Time (min)

  17. Slide 17: Seizure Potential of CX1763 (SSPA)

    Low Impact Ampakines - Tissue Model of Convulsions WN RespireRx respires Inc Seizure Potential of CX1763 (SSPA) Control 1763-600 701-600 i Me i oe, os an SUR _ ie KSToon Ooo# 701-600 PL (mv) P2 (mV) No. P oO 50 100, 150 200 250 Time (min)

  18. Slide 18: Ampakine Properties

    AMPAKINE Properties RespireRx Pharmaceuticals Inc Characteristics of Low Impact and High Impact AMPAKINE® Molecules Low Impact High Impact Mechanism of action Increases probability of Inhibits desensitization channel opening Bind to cyclothiazide site No Yes Increase EPSP in vivo. Yes Yes Increase l

  19. Slide 19: Project Endeavor - Ampakines: Verify Target Site Engagement

    Project Endeavor — Ampakines RespireRx 4 Pharmaceuticals Inc 1. Identify Target 2. Design Drugs 3. Verify Target Site Engagement + In Vitro Cellular Models « In Vivo Animal Models * Clinical Studies RespireRx Pharmaceuticals Inc © Medicines for Respiratory Diseases

  20. Slide 20: Identification of Key Rhythmogenic Neurons

    RespireRx eee Inc IDENTIFICATION OF KEY RHYTHMOGENIC NEURONS* ON Schematic diagram of a rhythmically-active medullary slice (700 pm) preparation used for recordings of preBétC neurons and XII nerves activity. PreBotC (light grey circles) inspiratory neuron display spontaneous inspiratory depolarizin

  21. Slide 21: AMPA Receptors Modulate Respiratory Neurons

    AMPA Receptors Modulate Respiratory Neurons GQ Resp ireRx RESPIRATORY FREQUENCY IS MODULATED VIA AMPA RECEPTORS 30s CNQX AMPA Funk et al. J. Neurophysiology 1997, 78:1414-20

  22. Slide 22: Ampakines Antagonize Opioid Induced Respiratory Depression

    AMPAKINES Antagonize Opioid Induced Respiratory Depression RespireRx Pharmaceuticals Inc mm CONTROL a vamco ecw Wasi our Sx ‘AMPLITUDE FREGUENGY AREA DURATION ‘CTZ (100uM) Cyclothiazide reverses DAMGO-induced respiratory drive depression in in vitro medullary slice of neonatal rat

  23. Slide 23: Ampakines Antagonize Opioid Induced Respiratory Depression

    AMPAKINES Antagonize Opioid Induced Respiratory Depression RespireRx Pharmaceuticals Inc DAMGOFGx717(100;M) co wo DAMGO + Cx717 vase our +4 3 INSTENT FREQUENCY (RELATIVE TO CONTROL) 8 ‘TIME (min) Ampakines Reverse Opioid-Induced Suppression of Respiratory Frequency in a medullary slice preparation,

  24. Slide 24: Ampakines Antagonize Opioid Induced Respiratory Depression

    RespireRx eoparen Inc AMPAKINES Antagonize Opioid Induced Respiratory Depression ; : iT Ls] pi MEAN + S.E.M. (RELATIVE TO CONTROL) [AMPLITUDE FREQUENCY AREA DURATION Ampakines Reverse Opioid-Induced Suppression of Respiratory Frequency ina medullary slice preparation, Integrated recordings of XII ne

  25. Slide 25: Ampakines Antagonize Opioid Induced Respiratory Depression

    RespireRx eoparen Inc AMPAKINES Antagonize Opioid Induced Respiratory Depression ; : WHOLE-BODY PLETHYSMOGRAPHIC RECORDINGS TAIL INFUSION OF OPIATES AND AMPAKINES Ren et al. (2006). American Journal of Respiratory and Critical Care Medicine. 174:1384-1391 Ren et al. (2009) Anesthesiology. 110(6):136

  26. Slide 26: Effect on Alfentanil-induced Respiratory Depression in Rats

    AMPAKINES Antagonize Opioid Induced Respiratory Depression ; : RespireRx Pharmaceuticals Inc 0 fs 5 F wo ‘ 3 2 =e 2 ¢ 35 38 $8 oy : Es Ee => PS 0 2 4 60 8 100 Time (min) Vehicle 5 10 20 Dose CX1739 (mgikg iv.) Effect on Alfentanil-induced Respiratory Depression in Rats Infusion of alfentanil (250 pg

  27. Slide 27: CX1942 and CX717 Reverse Opioid-Induced RD in Rats

    AMPAKINES Antagonize Opioid Induced Respiratory Depression ; : RespireRx Pharmaceuticals Inc Baseline (Before RD) +Opioid Min Volume (% of Baseline) 0 ec) 10 20 30 €X1942 (mg/kg) CX717 (mg/kg) CX1942 and CX717 reverse opioid-induced RD in rats

  28. Slide 28: Alfentanil-induced Respiratory Depression in Humans

    9 9) a. Ps) © 7] Z = is) 2 ) Alfentanil | i pression in Humans Resp pireRx Pharmaceuticals Inc 355 = j 3 30 4 a 2 Ez 3 E BH Placebo g 2- a 5 - “poe > 6 @ = Alfentanyl infusion - 100ng/ml oT: 5 0-4 3° $ 54 a 5 an gs a 0 T T T 1 5S in} 0 30 40 50 60 CO 2 concentration [mmHg]

  29. Slide 29: Ampakines Reduce Opioid-Induced Respiratory Depression in Phase 2A Trials

    Ampakines Reduce Opioid-Induced Respiratory Depression in Phase 2A Clinical Trials GQResp pireRx Pharmaceuticals Inc © So os $3 Placebo x717 Placebo x1739 ag 1500 mg* 900 me* o es ge 0 83s ge B& 10 * Approximately 15 and 10 eo mg/kg on a weight basis, e 15 p<01 i 35 respectively; comparable g5 7° p<

  30. Slide 30: Project Endeavor - Ampakines: Translational Studies to Demonstrate Efficacy

    Project Endeavor - Ampakines RespireRx Pharmaceuticals Inc 1. Identify Target 2. Design Drugs 3. Verify Target Site Engagement 4 . Translational Studies to Demonstrate Efficacy * Central Sleep Apnea - ADHD RespireRx Pharmaceuticals Inc © Medicines for Respiratory Diseases

  31. Slide 31: CX1739: Completed Phase 2A in Sleep Apnea - Single Dose

    CX1739: Completed Phase 2A in Sleep Apnea - Single Dose loAN) RespireRx pespiren Inc Design Randomized, double-blind, placebo-controlled study Population 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received either placebo or a sin

  32. Slide 32: Patient Selection: CX1739 More Effective in Mixed and Central Sleep Apneas

    Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas Obstructive Apneas Mixed Apneas 8B Apnea Index (Eventsfhr) oa Sass ‘Apnea Index (Eventsfhr) on Nh Oo ko @ AQ RespireRx rrespiren Inc Central Apnea 8 6 la 2 0. om Apnea Index (Eventemmr) ow oe Ra nT ff & 32

  33. Slide 33: Phase 2 Trial of CX717 in the Treatment of ADHD

    A Phase 2 Trial of CX717 in the Treatment of ADHD WB Screening visit Study Design Schematic PERIOD 1 PERIOD 2 WASHOUT / Treatment 4 / Treatment 4 / / / / / / Treatment 2 fi Treatment 2 H 7 H [oY i wieoow2w3 . Baselines Wt = W2 WS Baseliie2 Follow-up visit Assessments Assessments Telephone assessment

  34. Slide 34: CX717 Shows Significant Improvement in ADHD

    CX717 Shows Significant Improvement in ADHD ZN RespireRx respiret Inc OVERALL ADHR-RS HYPERACTIVITY INATTENTIVENESS HIGH DOSE COMPONENT (n=23) -ITT HIGH DOSE COMPONENT (n=23) -ITT Week 1 Week 2 Week 3 i) m0 aw) wae! Week Woes I < aw) wee Week Week 460 ‘ a I ani 4 600 4 Plato tH) Dose 40 000 [a= Plac

  35. Slide 35: CX717 May Be Superior to Strattera in the Treatment of ADHD

    CX717 May Be Superior to Strattera ® in the Treatment of ADHD: Comparison of ADHD-RS Scores RespireRx Strattera® Phase 3 Pivotal Trials CX 717 Clinical Trial STUDY 1 (LYAA) E CX717 (800mg) A (n=23) Week | 24 48 | -24 [| 025 Weeks | -5.6 297 | -41 {042 Week 1 38 8.0 42 4 [Endpe 6.0 95 | 35 [X36 Week

  36. Slide 36: Next Step: Phase Clinical Trial - CX1739 +/- AIH in SCI

    Next Step: Phase 2 Clinical Trial CX1739 +/- AIH in the Treatment of SCI ad RespireRx ee PeN Inc Unilateral hemi-transections at the level of the 2"¢ cervical vertebra are performed on rats and electrical activity is recorded from phrenic nerves, which innervate the diaphragm and contribute to the r

  37. Slide 37: Next Step: Phase Clinical Trial - CX1739 +/- AIH in SCI

    Next Step: Phase 2 Clinical Trial CX1739 +/- AIH in the Treatment of SCI GQ RespireRx Atel hea Inc Blinded, Placebo-controlled, Escalating-dose Study of CX1739, With and Without Acute Intermittent Hypoxia, in Patients with Incomplete Spinal Cord Injury Primary Objectives 1. Evaluate the safety of ac

  38. Slide 38: Pharmaceuticals Inc

    \ J Pharmaceuticals Inc

RespireRx Pharmaceuticals — Investor Presentation (November 2022) on 6ix